All In Biotech

NDA 022251 · Glaxosmithkline LLC

Lamictal Odt

Lamotrigine · Oral · Anti-epileptic Agent; Mood Stabilizer

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 8, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

191

49 Phase 3, 8 recruiting

FAERS reports

131,818

95,257 serious, 11,489 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS SKIN RASHES LAMICTAL can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving LAMICTAL. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking LAMICTAL as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate. In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by LAMICTAL include (1) coadministration of LAMICTAL with valproate...

What it is approved for

From the label in effect Oct 10, 2025.

LAMICTAL is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of LAMICTAL in the acute treatment of mood episodes has not been established. 1.1 Epilepsy Adjunctive Therapy LAMICTAL is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. Monotherapy LAMICTAL is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of LAMICTAL have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder LAMICTAL is indicated for the maintenance treatment of bipolar I disorder to delay the time...

Mechanism: The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy,...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • LAMICTAL ODT · LAMOTRIGINE 100MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • LAMICTAL ODT · LAMOTRIGINE 25MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • LAMICTAL ODT · LAMOTRIGINE 200MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • LAMICTAL ODT · LAMOTRIGINE 50MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lamotrigine" as an intervention, any sponsor and status, largest first.

All 191 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective10,339
  • rash8,692
  • seizure6,714
  • nausea6,457
  • off label use6,296
  • fatigue6,266
  • dizziness6,077
  • headache5,815
  • depression5,273
  • vomiting4,850
  • somnolence4,542
  • pyrexia4,522

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,016
20053,052
20063,557
20073,880
20082,377
20094,889
20103,761
20114,928
20125,259
20134,636
20145,129
20157,174
20167,478
20177,208
20188,199
20198,580
20207,704
20217,243
20226,632
20236,990
20247,677
20257,874
20265,574

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lamictal ODT (Lamotrigine)

2024 spending

$3.0M

Beneficiaries

241

1,808 claims

Per beneficiary

$12,567

$15.99 per unit

View as table
YearSpending
2020$3,599,389
2021$3,747,393
2022$4,001,776
2023$3,482,454
2024$3,028,719

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 896 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.